Hadzagic-Catibusic Feriha, Hasanbegovic Edo, Melunovic Melika, Zubcevic Smail, Uzicanin Sajra
Pediatric Clinic, University Clinical Center of Sarajevo, Bosnia and Herzegovina.
Med Arch. 2017 Aug;71(4):239-242. doi: 10.5455/medarh.2017.71.239-242.
Epilepsy is one of the most common neurological diseases in childhood and adolescence. Carbamazepine (CBZ) and valproate (VPA) have been widely used as the first generation of antiepileptic drugs (AED).
The aim of the study has been to evaluate and compare the effect of CBZ and VPA monotherapy on aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) serum levels in children.
The study has included 100 patients (boys 57/girls 43, age range 1 to 18 years), who have been treated with CBZ or VPA, as initial monotherapy, for at least 12 months. Patients with liver lesions or patients who have been treated with other drugs have been excluded from the study. The initial serum enzyme levels (AST, ALT and GGT) and after 12 months of treatment have been compared.
53/100 (53%) patients have been treated with CBZ and 47/100 (47%) patients have been treated with VPA.The initial level of enzymes were within the referece range. After one year-long treatment AST was elevated at 4/53 (7.5%) CBZ patients and 9/47 (19.15%) VPA patients (x2 test =3.965, p<0.05). ALT was elevated at 5/53 (9.4%) CBZ patients and 9/47 (19.15%) VPA patients (x2 test =6.953, p<0.05). GGT was elevated at 18/53 (34%) CBZ patients and 7/47 (14.9%) VPA patients (x2 test =4.831, p<0.05).
The levels of enzymes AST and ALT have been elevated statistically significant in VPA group and GGT in CBZ group.
癫痫是儿童和青少年时期最常见的神经系统疾病之一。卡马西平(CBZ)和丙戊酸盐(VPA)作为第一代抗癫痫药物(AED)已被广泛使用。
本研究旨在评估和比较CBZ和VPA单一疗法对儿童血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和γ-谷氨酰转移酶(GGT)水平的影响。
本研究纳入了100例患者(男孩57例/女孩43例,年龄范围1至18岁),他们接受了CBZ或VPA作为初始单一疗法治疗至少12个月。有肝脏病变的患者或接受过其他药物治疗的患者被排除在研究之外。比较了初始血清酶水平(AST、ALT和GGT)以及治疗12个月后的水平。
100例患者中,53例(53%)接受了CBZ治疗,47例(47%)接受了VPA治疗。酶的初始水平在参考范围内。经过一年的治疗,4/53(7.5%)接受CBZ治疗的患者AST升高,9/47(19.15%)接受VPA治疗的患者AST升高(χ²检验=3.965,p<0.05)。5/53(9.4%)接受CBZ治疗的患者ALT升高,9/47(19.15%)接受VPA治疗的患者ALT升高(χ²检验=6.953,p<0.05)。18/53(34%)接受CBZ治疗的患者GGT升高,7/47(14.9%)接受VPA治疗的患者GGT升高(χ²检验=4.831,p<0.05)。
VPA组中AST和ALT酶水平升高具有统计学意义,CBZ组中GGT酶水平升高具有统计学意义。